Collaborative Clinical Study Aims to Advance Treatment of Kidney and Prostate Cancer with 3D Printing
Patient-specific and highly personalized 3D models being studied for
their ability to enable surgeons to more effectively conduct
pre-surgical planning and intra-operative collaboration
Stratasys J750 3D Printer empowers researchers to accurately
replicate complex organs and pathologies in highly accurate, full-color
3D printed physical models
MINNEAPOLIS & REHOVOT, Israel–(BUSINESS WIRE)–Stratasys
(NASDAQ: SSYS), a global leader in applied additive technology
solutions, today announced a new clinical study is being conducted with
the New York University (NYU) School of Medicine – aimed at advancing
diagnosis and treatment of complex kidney and prostate tumors through
imaging and 3D printing. These patient-specific 3D models of organs and
their associated pathologies may empower surgeons and researchers to
conduct more accurate pre-operative assessment and inter-operative
guidance, potentially improving surgical outcomes.
The two-year clinical trial is being led by Nicole Wake – a pre-doctoral
researcher at the Sackler Institute of Graduate Biomedical Sciences at
NYU School of Medicine. The study is specifically targeted at analyzing
how patient-specific multi-colored physical tumor models, printed on the
Stratasys J750 3D Printer, can potentially change and improve the
quality of patient care.
Under the randomized, controlled study, Wake and her research team are
3D printing kidney and prostate cancer models for a sample of the
participating 300 patients – measuring the specific impact each has on
pre-surgical planning versus traditional 2D visualization approaches.
Subjects are separated into three treatment categories to analyze and
compare conventional pre-operative 2D imaging, augmented reality models,
and next-generation 3D printed models.
“3D printing holds a lot of potential in assisting with surgical
planning, and as surgeons, we are always looking at ways to improve
outcomes for our patients,” says study co-author William C. Huang, MD,
associate professor of urology at NYU School of Medicine. “We are
pleased to be leading a study examining how 3D-printed models may
improve the surgical planning process and ultimately impact patient
care.”
“Surgeons and hospitals continuously search for ways to improve the
quality of patient care while also reining in procedural costs. In case
studies and small trials, 3D printed patient-specific models have shown
tremendous potential to improve clinical outcomes and cost savings,”
said Scott Rader, GM of Healthcare Solutions at Stratasys. “This
clinical study will be one of the first large-scale studies that can
finally quantify the impact of 3D printing.”
With its unique ability to produce parts in over 360,000 colors,
textures, gradients, and transparencies – the Stratasys J750 3D Printer
delivers medical models with a broad array of characteristics that
replicate the look, feel and function of organic structures. Built
directly from patient scans, these models match the widest array of
medical properties – from soft tissue to hard bone. Advanced modeling
not only guides surgeons in the operating room, but enables patients to
better visualize proposed treatments and course of care.
Moving forward, the clinical study is expected to continue into 2018.
During the next phase of the project, researchers will begin to explore
quantitative patient outcomes.
Stratasys (NASDAQ: SSYS) is a global leader in applied additive
technology solutions for industries including Aerospace, Automotive,
Healthcare, Consumer Products and Education. For nearly 30 years, a deep
and ongoing focus on customers’ business requirements has fueled
purposeful innovations—1,200 granted and pending additive technology
patents to date—that create new value across product lifecycle
processes, from design prototypes to manufacturing tools and final
production parts. The Stratasys 3D printing ecosystem of solutions and
expertise—advanced materials; software with voxel level control;
precise, repeatable and reliable FDM and PolyJet 3D printers;
application-based expert services; on-demand parts and industry-defining
partnerships—works to ensure seamless integration into each customer’s
evolving workflow. Fulfilling the real-world potential of additive,
Stratasys delivers breakthrough industry-specific applications that
accelerate business processes, optimize value chains and drive business
performance improvements for thousands of future-ready leaders around
the world.
Corporate Headquarters: Minneapolis, Minnesota and
Rehovot, Israel.
Online at: www.stratasys.com,
http://blog.stratasys.com and LinkedIn.
Stratasys is a registered trademark, and the Stratasys J750 and
Stratasys signet are trademarks or registered trademarks of Stratasys
Ltd. and or its subsidiaries or affiliates. All other trademarks belong
to their respective owners.
Attention Editors, if you publish reader-contact information, please use:
- USA 1-877-489-9449
- Europe/Middle East/Africa +49-7229-7772-0
- Asia Pacific +852 3944-8888
Contacts
Stratasys Media Contacts
Stratasys
Arita
Mattsoff / Joe Hiemenz
Stratasys
Tel. +972 74 745 4000 (IL)
Tel.
+1 952 906 2726 (US)
[email protected]
[email protected]
or
Asia
Pacific and Greater China
Stratasys AP
Alice Chiu
Tel.
+852 3944 8888
[email protected]
or
Brazil
Clezia
Martins Gomes
GPCOM
Tel. +55 (11) 3129 5158
[email protected]
or
North
America
Craig Librett
Stratasys
Tel. +1 518 424 2497
[email protected]
or
Japan
and Korea
Stratasys Japan
Aya Yoshizawa
Tel. +81 90
6473 1812
[email protected]
or
Europe
Jonathan
Wake / Miguel Afonso
Incus Media
Tel. +44 1737 215200
[email protected]
or
Mexico,
Central America, Caribe and South America
Stratasys Mexico
Yair
Canedo
Tel. +52 55 4169 4181
[email protected]
